Cipla cancer drugs cheaper by up to 64%
- Congress says Togadia spreading venom; EC seeks recording of alleged hate speech
- Akhilesh Yadav tears into Narendra Modi bastion on maiden visit to Gujarat, says third front ready to govern
- Proponents of Article 370 should say how it has helped J&K: Rajnath Singh
- 1984 riots: Akalis protest over Capt Amarinder Singh's clean chit to Jagdish Tytler
- IPL 7 Live Cricket Score, CSK vs DD: CSK register comprehensive victory over hapless DD
Drugmaker Cipla cut prices of three cancer drugs between 50 percent and 64 percent with immediate effect, after it announced similar price cuts for three drugs early this year.
Lung cancer drug Erlocip would cost 9,900 rupees for 30 tablets instead of 27,000 rupees earlier, while breast cancer treatment Docetax would be priced 1,650 rupees instead of 3,300 rupees, Cipla said in a statement on Thursday.
Cipla last month won a case against Roche Holding, which accused the Indian company of infringing patent on cancer drug Tarceva, which Cipla sells under the brand name Erlocip.
Capegard, another drug to treat metastatic colorectal and colon caner, would be priced 600 rupees for 10 tablets instead of 1,200 rupees, it said.
- Jet Airways likely to terminate services of contract employees
- No link between mobile phone radiation and cancer, says Padma awardee doctor
- Mamata’s celebs revel in new role
- ‘Goa mining ban removal to breathe new life into sector’
- TCS, Mitsubishi arms merge to form tech firm in Japan
- ‘RSS worry for majority community too’